Daisuke Kawakita1, Toshitaka Nagao2, Hideaki Takahashi3, Satoshi Kano4, Yoshitaka Honma5, Hideaki Hirai2, Natsuki Saigusa2, Kohei Akazawa6, Kaori Tani6, Hiroya Ojiri7, Kiyoaki Tsukahara8, Hiroyuki Ozawa9, Kenji Okami10, Takahito Kondo11, Takafumi Togashi12, Chihiro Fushimi13, Tomotaka Shimura14, Akira Shimizu8, Isaku Okamoto8, Takuro Okada8, Yorihisa Imanishi9, Yoshihiro Watanabe9, Kuninori Otsuka9, Akihiro Sakai10, Koji Ebisumoto10, Yuichiro Sato12, Keisuke Yamazaki15, Yushi Ueki15, Toyoyuki Hanazawa16, Yuki Saito17, Mizuo Ando18, Takashi Matsuki19, Masato Nakaguro20, Yukiko Sato21, Makoto Urano22, Yoshitaka Utsumi2, Shinji Kohsaka23, Takashi Saotome24, Yuichiro Tada25. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 2. Department of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. 3. Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan. 4. Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 5. Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. 6. Department of Medical Informatics, Niigata University Medical and Dental Hospital, Chuo-ku, Niigata, Japan. 7. Department of Radiology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. 8. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. 9. Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 10. Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan. 11. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan. 12. Department of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan. 13. Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan. 14. Department of Otolaryngology, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Japan. 15. Department of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan. 16. Department of Otorhinolaryngology/Head & Neck Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan. 17. Department of Otolaryngology - Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. 18. Department of Otorhinolaryngology/Head & Neck Surgery, Okayama University Graduate School of Medicine, Kita-ku, Okayama, Japan. 19. Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Minami-ku, Sagamihara, Japan. 20. Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan. 21. Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan. 22. Department of Diagnostic Pathology, Bantane Hospital, Fujita Health University, School of Medicine, Nakagawa-ku, Nagoya, Japan. 23. Division of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. 24. Division of Medical Oncology, Matsudo City Hospital, Matsudo, Japan. 25. Department of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan.
Abstract
Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.
Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.
Authors: M J M Uijen; G Lassche; A C H van Engen-van Grunsven; C M L Driessen; C M L van Herpen Journal: Oral Oncol Date: 2022-01-04 Impact factor: 5.337
Authors: R Kurzrock; D W Bowles; H Kang; F Meric-Bernstam; J Hainsworth; D R Spigel; R Bose; H Burris; C J Sweeney; M S Beattie; S Blotner; K Schulze; V Cuchelkar; C Swanton Journal: Ann Oncol Date: 2019-12-09 Impact factor: 32.976
Authors: Aurélien Marabelle; Marwan Fakih; Juanita Lopez; Manisha Shah; Ronnie Shapira-Frommer; Kazuhiko Nakagawa; Hyun Cheol Chung; Hedy L Kindler; Jose A Lopez-Martin; Wilson H Miller; Antoine Italiano; Steven Kao; Sarina A Piha-Paul; Jean-Pierre Delord; Robert R McWilliams; David A Fabrizio; Deepti Aurora-Garg; Lei Xu; Fan Jin; Kevin Norwood; Yung-Jue Bang Journal: Lancet Oncol Date: 2020-09-10 Impact factor: 41.316
Authors: C Fushimi; Y Tada; H Takahashi; T Nagao; H Ojiri; T Masubuchi; T Matsuki; K Miura; D Kawakita; H Hirai; E Hoshino; S Kamata; T Saotome Journal: Ann Oncol Date: 2018-04-01 Impact factor: 32.976